GlassScriptPhysician profile
Omkar U Vaidya
NPI 1518117670
$1,110.03
in general payments reported to CMS, 2019-2025
21 companies · $415 in 2025
The $415 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $160 · 2020: $94.47 · 2023: $237 · 2024: $203 · 2025: $415.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $856.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $856.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intercept Pharmaceuticals, INC. | $173.57 | 2023 | Ocaliva |
| Genzyme Corporation | $146.88 | 2024 | |
| Madrigal Pharmaceuticals | $141.32 | 2025 | Rezdiffra |
| Lilly USA, LLC | $80.69 | 2024-2025 | Mounjaro, Zepbound |
| Exact Sciences Corporation | $80.33 | 2025 | Cologuard Collection Kit |
| Daiichi Sankyo INC. | $71.91 | 2019-2020 | |
| Mallinckrodt Enterprises LLC | $64.41 | 2019 | |
| Hologic Sales and Service, LLC | $44.45 | 2025 | Aptima, Thinprep 2000 Processor |
| Amgen INC. | $43.83 | 2019-2020 | |
| Organon LLC | $38.57 | 2025 | Vtama |
| Novo Nordisk INC | $30.68 | 2024-2025 | Wegovy |
| Regeneron Healthcare Solutions, INC. | $23.62 | 2024 | Dupixent |
| Csl Behring | $22.14 | 2023 | Haegarda |
| Leo Pharma INC. | $22.14 | 2023 | Adbry |
| Otsuka America Pharmaceutical, INC. | $21.66 | 2019 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Heartflow, INC. | $19.83 | 2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $19.46 | 2023 | Xifaxan |
| Pfizer INC. | $18.62 | 2019 | |
| Opko Pharmaceuticals, LLC | $17.02 | 2020 | |
| Amicus Therapeutics, INC. | $16.52 | 2019 | |
| Echosens North America, INC. | $12.38 | 2025 | Fibroscan |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Omkar Vaidya listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.